Introduction
Non-valvular atrial fibrillation (AF) increases the risk of stroke and systemic embolism (SSE), leading to substantial morbidity and mortality. 1 Whether the risk of stroke is affected by the type, duration, and frequency of AF has been debated for several years. Pooled analysis of the Stroke Prevention in Atrial Fibrillation (SPAF) trials demonstrated a comparable risk of stroke in patients with paroxysmal and sustained AF treated with aspirin. 2 3, 4 In contrast, recently published data from the ROCKET-AF trial identified a higher rate of adverse outcomes in anticoagulated patients with persistent compared to paroxysmal AF, with borderline statistical significance for SSE (2.2 versus 1.7 per 100 patient-years; p=0.048) and significantly higher all-cause mortality (4.8 versus 3.5 per 100 patient-years; p=0.006). 5 Similar findings of increased stroke risk have been published from other studies using both vitamin K antagonists (VKA) and non-VKA oral anticoagulants (NOAC), including the SPORTIF and ARISTOTLE trials. 6, 7 Global surveys suggest that permanent AF is the most common type, accounting for around 50% of AF patients who also have a substantial burden of co-morbidities. This includes heart failure, present in 56% of patients with permanent AF, compared to 33% in paroxysmal and 44% in persistent AF. 8 Practice guidelines on AF management address the prevention of SSE regardless of the type of AF, based on known risk factors in this patient population. 9, 10 The CHA 2 DS 2 -VASc score is a commonly-used risk prediction score for SSE, focusing on clinical risk factors. 11 The "C" criterion represents the higher stroke risk associated with recent decompensated heart failure irrespective of ejection fraction (thus including heart failure with reduced and preserved ejection fraction, as well as moderate-severe left ventricular systolic impairment on echocardiography). 12, 13 Moreover, the combination of AF and heart failure is associated with an increased risk of all-cause mortality and hospital admission, with numerous studies suggesting that AF may be associated with progression of heart failure. [14] [15] [16] [17] [18] The impact of the type of AF on outcomes such as stroke and death in anticoagulated AF patients with and without heart failure remains controversial, particularly in regards to permanent compared to non-permanent AF. As both incidence and prevalence of AF are rapidly increasing 19 , the burden of heart failure can be expected to rise proportionally. To investigate these aspects further, we reviewed data from the AMADEUS trial (Evaluating the Use of SR34006
Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation), a multicentre, randomized, open-label study comparing fixed-dose idraparinux with dose-adjusted VKA therapy in AF patients with an indication for long-term anticoagulation. 20 We hypothesised that adverse outcomes would be more prevalent in permanent AF and aimed to assess the impact of heart failure in anticoagulated patients, accounting for the type of AF.
Methods

Study population
The design of the AMADEUS trial has previously been described. 20, 21 In brief, the Exclusion criteria included the inability to provide consent, contraindication or other requirement for anticoagulation, calculated creatinine clearance of <10 mL/min, breastfeeding, pregnancy and recent or anticipated invasive procedures with potential for uncontrolled bleeding. We examined the population according to type of AF, considering non-permanent AF (comprising paroxysmal and persistent) versus permanent AF. The presence of investigator-documented heart failure at baseline was used to sub-categorise the population.
Definitions of endpoint
This post-hoc analysis of the AMADEUS trial used pooled data from both the VKA and idraparinux arms on an intention to treat basis. The primary outcome of this analysis was the composite of cardiovascular (CV) death and SSE. Stroke included ischaemic, haemorrhagic or undefined causes that resulted in a focal neurological deficit of sudden onset, with a corresponding defect on brain imaging. Systemic embolism was confirmed by angiography, surgery, or autopsy. The safety outcome of the present analysis was major bleeding in the VKA arm of the trial, defined as bleeding that was fatal, intracranial or affecting another critical anatomical site, overt bleeding with a drop of haemoglobin ≥20 g/L or requiring transfusion of two or more units of erythrocytes. All suspected outcome events were classified by the original AMADEUS central adjudication committee who were blinded to treatment assignment.
Statistical analysis
The characteristics of the patients are reported as percentages and mean ± standard deviation (SD). Comparisons between patients with and without pre-existing heart failure were made using Fisher's exact test when comparing categorical variables and t-tests or the MannWhitney U-test, as appropriate for continuous variables. Outcomes by type of AF (permanent AF versus non-permanent) were calculated by the overall rate of adverse events per 100 patient-years after adjustment for age and sex. A Cox proportional hazard model was used to identify the independent characteristics associated with outcomes during follow-up.
The multivariate model included adjustment for age, sex, creatinine (log-transformed), hypertension, diabetes mellitus and previous stroke/TIA/thromboembolism and CAD. The results are expressed as hazard ratios (HR) and 95% confidence intervals (CI). Schoenfeld residuals were used to confirm proportional hazards over time. All interactions were evaluated in the multivariate Cox model, including two post-hoc defined exploratory analyses according to treatment allocation and time in therapeutic range (TTR) for those randomised to VKA. The adjusted probabilities comparing permanent and non-permanent AF were analysed using an adjusted logistic regression model, with heart failure interaction determined using a likelihood ratio test. Kaplan-Meier curves were assessed using a log-rank test. A two-tailed p-value <0.05 was considered statistically significant. Analyses were performed using SPSS (version 21) and Stata (version 13.1).
Results
Atrial fibrillation was present in 4556 patients. Non-permanent AF accounted for 2072 patients (46% of cohort), of which 339 (16%) had pre-existing heart failure. Permanent AF was documented in 2484 patients (54% of cohort), with a higher burden of heart failure that included 730 patients (29%); p<0.001 compared to non-permanent AF. Baseline characteristics according to type of AF are presented in Table 1 . Patients with permanent AF were older, with more men, a higher rate of diabetes, less hypertension and overall a marginally higher CHA 2 DS 2 -VASc score. Patients with pre-existing heart failure had a higher frequency of men, diabetes, renal impairment and CAD than those without a history of heart failure (see Supplementary Table) . patients in permanent AF (3.0/100person-years) and 31 patients in non-permanent AF (1.7/100 person-years). There were numerically more outcomes among those with permanent AF for each component of the primary outcome (CV death and SSE; see Table 2 ) but these differences were not significant. The hazard ratio for the primary outcome comparing permanent versus non-permanent AF was 1.73 in univariate analysis (95% CI 1.13-2.64; p=0.01) and 1.66 following multivariate adjustment (95% CI 1.08-2.55; p=0.02); see Table 3 .
The Kaplan-Meier event curves are depicted in Figure 1 (log-rank p=0.01). Other variables independently associated with the primary outcome were creatinine, prior cerebrovascular events and previous CAD. In exploratory analyses, neither allocation to treatment arm (VKA or Idraparinux) nor TTR in VKA patients interacted with the association of AF type and the primary outcome (p=0.19 and 0.38 respectively).
permanent and non-permanent AF in the sub-groups with and without heart failure. However, the same trend of an increase in adverse events in those with permanent AF compared to nonpermanent AF was evident, regardless of heart failure status (see Table 2 ). The interaction pvalue between AF type and heart failure status for the primary outcome was 0.76. Figure 2 displays the adjusted probabilities of the primary outcome according to the four sub-groups, demonstrating a similar increase in adverse events with concomitant heart failure in both permanent and non-permanent AF.
Bleeding outcomes in the warfarin arm of the trial are listed in Table 4 . Major bleeding, and a composite with CV death and SSE, were not significantly different between patients with permanent and non-permanent AF, irrespective of the presence of heart failure.
Discussion
Our analysis demonstrates that in anticoagulated patients, permanent AF is associated with a higher risk of the composite endpoint of CV death, stroke or systemic embolism compared to non-permanent forms of AF. This finding was maintained even after adjustment for potential confounders that could influence the risk of events. Importantly, we did not identify any interaction with pre-existing heart failure, confirming that the adverse risk associated with permanent AF is independent of heart failure status.
Atrial fibrillation results in a considerable burden on patients and healthcare systems, leading
to an increased risk of stroke, hospital admission and death. 22 Permanent AF is the most common form and is associated with numerous other cardiovascular risk factors. 8 The impact of AF, particularly in regard to type of AF, has previously been difficult to define due to variation in the use of anticoagulation, differences in comorbidities and the presence of heart failure. Concomitant AF and heart failure are common in clinical practice and regardless of which comes first, patients have a much poorer prognosis. The Framingham study showed that in AF patients, heart failure was associated with significantly increased mortality (HR 16 In a meta-analysis of heart failure patients, the presence of AF was associated with higher risk of death both in randomized trials and observational studies (odds ratio 1.40, 95% CI 1.32-1.48 and 1.14, 95% CI 1.03-1.26, respectively). 23 Activation of the renin-angiotensin system and chronic atrial stretch due to structural heart disease can lead to histological changes in the atria. 24, 25 Subsequently, this atrial remodelling is more likely to be associated with longer AF episodes and other complications. 26, 27 Indeed, Taillandier et al found that permanent AF in patients with heart failure is associated with a higher risk of death and hospitalization for heart failure, mostly in patients with preserved left ventricular ejection fraction. 28 These results suggested that the duration of AF episodes might be a potential risk factor for adverse outcomes in patients with heart failure, in addition to comorbidities and hemodynamic status.
In general, the duration of AF episodes leading to thrombus formation are poorly known, and therefore clinicians have usually been less likely to treat short and infrequent episodes of AF with oral anticoagulation than patients with persistent or permanent AF. 29 30 In the Stockholm Cohort Study on Atrial Fibrillation, ischemic strokes were twice as common in paroxysmal AF than predicted in the general population, but the same in paroxysmal AF and permanent AF. 31 Of note, anticoagulation with VKA was only prescribed at baseline in 28%
and 49%, respectively, and none of these analyses included consistently anticoagulated patients. In contrast, we were able to study the residual risk of adverse outcomes in anticoagulated patients. Following consistent anticoagulation with either dose-adjusted warfarin or fixed-dose idraparinux, our data demonstrate that permanent AF was associated with worse outcomes. Similarly, in sub-studies of recent randomised trials on non-VKA anticoagulants, patients with persistent or permanent AF had a significantly higher rate of thromboembolic events compared to those with paroxysmal AF. 5, 7 Heart failure attenuated the risk of adverse outcomes similarly in both permanent and nonpermanent AF patients. In patients with AF, hearty failure has been strongly associated with SSE and mortality, and independently adds to risk prediction. 13 32 However, the mechanisms underlying this association remain an area of ongoing research. Future studies of heart failure and AF should consider these aspects to improve our understanding of their complex inter-relationship.
failure, patients with permanent AF have considerable risk of residual morbidity and mortality, even after anticoagulation. This finding has important implications for AF treatment strategies and necessitates on-going management and the identification of where residual risks can be reduced further after anticoagulation.
Limitations
These results are based on a post-hoc analysis of the AMADEUS trial, and should be interpreted as hypothesis-generating. The AMADEUS population was at relatively low risk of both ischemic stroke and bleeding events compared with "real-world" patients, with limited statistical power for sub-group comparisons. We accepted the definition of heart failure as defined in the AMADEUS trial but were unable to delineate those patients with reduced or preserved ejection fraction. Nevertheless, stroke outcomes in AF patients do not appear to differ according to ejection fraction. 12, 33 Data regarding heart failure therapies were also not available, which may have affected outcomes differently according to type of AF.
Conclusion
This post-hoc analysis of the AMADEUS trial confirms a significantly higher risk of cardiovascular death, stroke or systemic embolism in anticoagulated patients with permanent AF compared to non-permanent AF. Concomitant heart failure attenuates the residual risk of adverse outcomes after anticoagulation similarly in both permanent and non-permanent AF. Collaborative Group (BB-meta-HF).
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